Infectious Diseases and Vaccine Landscape 2026
Why Australia and New Zealand are strategically positioned for successful clinical trials. The global infectious disease environment continues to shift at pace in 2026, driven by: Influenza remains the clearest example of how quickly pathogens can adapt, and how the industry must respond. A newly dominant influenza A(H3N2) variant, commonly referred to as the “subclade…
Regulatory Strategy for Drug and Device Development
Regulatory Strategy for Drug and Device Development. Why it must start on Day One. In the fast-paced world of life sciences innovation, the drive to “get moving” can be irresistible. Teams dive into development, eager to demonstrate progress.Yet the companies that succeed long-term are those that pause first to plan, align, and build a regulatory…
Life Sciences Expansion Strategies Greater Bay Area – China
China’s Greater Bay Area (GBA) initiative aims to create a single, integrated economic zone, fostering innovation, connectivity, and environmental sustainability. We explore how the Greater Bay Area (GBA) is transforming life sciences and medical device access in China, with regulatory benefits and streamlined market entry opportunities. What is the Greater Bay Area (GBA)? The Greater…
Australia’s TGA Priority Review Pathway
How Australia’s TGA Priority Review Pathway Helps Speed Up Access to New Medicines. The ultimate goal of every regulatory submission is patient access. Whether seeking approval for a new prescription medicine or an additional indication for an existing drug, the objective remains the same — providing patients with the best possible treatment options as quickly…
The Pointy End of the TGA (PI) Reformatting Transition Period
By now, we should all be very familiar with the new Form for providing Product Information (PI) for Australia. Each time you make a change to a PI, be it safety-related or otherwise, you’re required to provide the updated PI to TGA in the new format. The looming deadline for marketed product PIs to be
MEDSAFE NZ Moves Ahead in 2020
Since 2015, Medsafe NZ, the New Zealand Medicines and Medical Devices Safety Authority, has been working on a new therapeutic products regulatory regime to replace and modernise the regulatory arrangements for medicines, and provide regulation of all therapeutic products. Whilst we are still waiting for the progression of the Therapeutic Products Bill through parliament, the
Disclaimer:
The information provided is intended for general informational purposes only and does not constitute legal, professional, or any other type of advice. While every effort has been made to ensure the accuracy and reliability of the information, the authors make no representations or warranties, express or implied, regarding the completeness, suitability, or applicability of the content to specific products or situations.